STOKE THERAPEUTICS, INC.
About STOKE THERAPEUTICS, INC.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, the company develops antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for Dravet syndrome. The company is publicly traded on Nasdaq under STOK and is headquartered in Bedford, Massachusetts.
- 🔗 Stoke Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering - Stoke Therapeutics
- 🔗 Stoke Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements
- 🔗 About Stoke Therapeutics Inc (STOK) - Investing.com NG
- 🔗 Investors & News - Stoke Therapeutics
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Total funding of $131M prior to 2019 IPO of $142.2M
- Developing STK-001 for Dravet syndrome and STK-002 for ADOA
- Employs proprietary TANGO platform for protein upregulation via ASOs
- Revenue reported in $100M-$500M range as of late 2025
- 117 employees as of December 2022
Ask StreetZero about STOKE THERAPEUTICS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account